| Dr Shaun Randolph Senter, MD | |
|
3211 N Northhills Blvd, Suite 110, Fayetteville, AR 72703-4007 | |
| (479) 571-4338 | |
| (479) 571-4015 |
| Full Name | Dr Shaun Randolph Senter |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 20 Years |
| Location | 3211 N Northhills Blvd, Fayetteville, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972659480 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Washington Regional Medical Center | Fayetteville, AR | Hospital |
| North Arkansas Regional Medical Center | Harrison, AR | Hospital |
| Siloam Springs Regional Hospital | Siloam springs, AR | Hospital |
| Mercy Hospital Northwest Arkansas | Rogers, AR | Hospital |
| Northwest Medical Center-springdale | Springdale, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Washington Regional Medical System | 8820995434 | 219 |
News Archive
C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance imaging procedure.
REACH Health, Inc., a leading provider of comprehensive clinical telemedicine solutions, today announced that it has launched REACH Physician Services for Tele-Stroke, Tele-Neurology and Tele-ICU call coverage.
The Eunice Kennedy Shriver National Institute of Child Health & Human Development has awarded a $256,000 grant to BioAesthetics Corp., a Tulane University spin-out company, to develop a new graft for treating pelvic organ prolapse (POP).
Chronic obstructive pulmonary disease (COPD) is considered the fourth most common cause of death in the United States. Usually the precursor to this life-threatening lung disease is a chronic bronchitis. Partially destroyed alveoli and an over-inflation of the lungs, known as emphysema, are serious side effects. However, the subtle differences in the tissue are barely discernable in standard X-ray images.
MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.
› Verified 6 days ago
| Entity Name | Washington Regional Medical System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679890966 PECOS PAC ID: 8820995434 Enrollment ID: O20100812000027 |
News Archive
C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance imaging procedure.
REACH Health, Inc., a leading provider of comprehensive clinical telemedicine solutions, today announced that it has launched REACH Physician Services for Tele-Stroke, Tele-Neurology and Tele-ICU call coverage.
The Eunice Kennedy Shriver National Institute of Child Health & Human Development has awarded a $256,000 grant to BioAesthetics Corp., a Tulane University spin-out company, to develop a new graft for treating pelvic organ prolapse (POP).
Chronic obstructive pulmonary disease (COPD) is considered the fourth most common cause of death in the United States. Usually the precursor to this life-threatening lung disease is a chronic bronchitis. Partially destroyed alveoli and an over-inflation of the lungs, known as emphysema, are serious side effects. However, the subtle differences in the tissue are barely discernable in standard X-ray images.
MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shaun Randolph Senter, MD 3211 N Northhills Blvd, Suite 110, Fayetteville, AR 72703-4007 Ph: (479) 571-4338 | Dr Shaun Randolph Senter, MD 3211 N Northhills Blvd, Suite 110, Fayetteville, AR 72703-4007 Ph: (479) 571-4338 |
News Archive
C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance imaging procedure.
REACH Health, Inc., a leading provider of comprehensive clinical telemedicine solutions, today announced that it has launched REACH Physician Services for Tele-Stroke, Tele-Neurology and Tele-ICU call coverage.
The Eunice Kennedy Shriver National Institute of Child Health & Human Development has awarded a $256,000 grant to BioAesthetics Corp., a Tulane University spin-out company, to develop a new graft for treating pelvic organ prolapse (POP).
Chronic obstructive pulmonary disease (COPD) is considered the fourth most common cause of death in the United States. Usually the precursor to this life-threatening lung disease is a chronic bronchitis. Partially destroyed alveoli and an over-inflation of the lungs, known as emphysema, are serious side effects. However, the subtle differences in the tissue are barely discernable in standard X-ray images.
MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.
› Verified 6 days ago
Lauren Cantwell Paulk, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1706 E Joyce Blvd Ste 2, Fayetteville, AR 72703 Phone: 479-966-9370 | |
David R Crittenden, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1408 E Elmwood Dr, Fayetteville, AR 72703 Phone: 479-442-0759 | |
Kim R Agee, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 3344 N Futrall Dr, Fayetteville, AR 72703 Phone: 479-521-8200 Fax: 479-582-7310 | |
Dr. David A Churchill, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3211 N Northhills Blvd, Suite 110, Fayetteville, AR 72703 Phone: 479-571-4338 Fax: 479-571-4015 | |
Dr. Marlan Levan Rhame Iii, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1100 N College Ave, Fayetteville, AR 72703 Phone: 479-443-4301 Fax: 479-587-5929 | |
Waqar M Mehal, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 12 E Appleby, Suite 101, Fayetteville, AR 72703 Phone: 479-463-4444 Fax: 479-463-4499 | |
Dr. Juan I Lombeida, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3232 N North Hills Blvd, Fayetteville, AR 72703 Phone: 479-587-1700 |